Phenomex stock.

The fair value is based on 24,945,611 shares of PhenomeX common stock at $ 1.28 per share on March 21, 2023 issued to IsoPlexis stockholders. IsoPlexis stockholders received 0.612 shares of PhenomeX stock for …PhenomeX (Nasdaq: CELL), the functional cell biology company, today announced that Yan Zhang, Ph.D., has been named chief commercial officer (CCO), effective immediately. In addition to Dr. Zhang ...EMERYVILLE - PhenomeX, Inc. (Nasdaq: CELL), a life sciences tools company, today reported financial results for the first quarter ended March 31, 2023. Following the completion of Berkeley Lights' acquisition of IsoPlexis on March 21, 2023, the newly combined company was rebranded as PhenomeX and is positioned to be the leading provider of life sciences solutions that have the greatest impact ...Sep 29, 2023 · PhenomeX Inc. (BLI.NYSE) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock PhenomeX Inc. | Nyse: BLI | Nyse PhenomeX Inc. (Nasdaq: CELL), a functional cell biology company, announced the Opto® Memory B Discovery Human workflow, further expanding diversity of antibodies customers can discover on the ...

Aug 14, 2023 · PhenomeX reiterates full year 2023 revenue to be in the range of $75 to $85 million dollars and updates its GAAP gross margin target range to be 57% to 60%, as a result of purchase price ...

PhenomeX Inc. (Nasdaq: CELL), ... Don’t go anywhere, rather, stay in the stock market, appears to be the recommendation of JPMorgan’s global investment strategist Madison Faller, ...PhenomeX Reports Second Quarter 2023 Financial Results and Provides Business Update PR Newswire - Mon Aug 14, 3:05PM CDT /PRNewswire/ -- PhenomeX, Inc. (Nasdaq: …Web

Aug 14, 2023 · Operating expenses were $53.3 million, inclusive of $3.7 million of stock-based compensation, for the second quarter of 2023, compared to $38.5 million, inclusive of $6.6 million of stock-based ... As a result of the transaction closing, PhenomeX common stock will no longer be listed for trading on the Nasdaq Global Market. Also, PhenomeX will soon be changing its name.Get the latest PhenomeX detailed stock quotes, stock trade data, stock price info, and performance analysis, including PhenomeX Stock investment advice, charts, stats and …WebFeb 23, 2023 · Recent Highlights. Achieved revenue of $78.6 million for the full year 2022, representing an 8% decrease over the prior year;; Announced the acquisition agreement of IsoPlexis to create a premier functional cell biology company, PhenomeX, when the merger closes, would accelerate the transformation of Berkeley Lights from a technology platform company into a growing, profitable, and sustainable ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Ex...

0001193125-23-226363.txt : 20230831 0001193125-23-226363.hdr.sgml : 20230831 20230831161100 ACCESSION NUMBER: 0001193125-23-226363 CONFORMED SUBMISSION TYPE: SC TO-T PUBLIC DOCUME

These 20 growth stocks are worth considering on a pullback, says Citi MarketWatch. Thursday, August 17, 2023. 11:27 AM ET. PhenomeX stock rallies by 137% after buyout offer from Bruker MarketWatch. Friday, October 21, 2022. 09:19 AM ET. Bruker started at buy with $70 stock price target at UBS MarketWatch. Thursday, September …The fair value is based on 24,945,611 shares of PhenomeX common stock at $ 1.28 per share on March 21, 2023 issued to IsoPlexis stockholders. IsoPlexis stockholders received 0.612 shares of PhenomeX stock for …PhenomeX Inc. (Nasdaq: CELL), a functional cell biology company, today announced it will showcase their latest optofluidic and proteomic technologies, along with customer partners, at two upcoming ...View %COMPANY_NAME% CELL investment & stock information. Get the latest %COMPANY_NAME% CELL detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. ... PHENOMEX INC (CELL ...Company profile page for Phenomenex Inc including stock price, company news, press releases, executives, board members, and contact information

-- Price: 4.42, Change: -0.55, Percent Change: -11.07 ... | June 8, 2023Bird Mergersub Corporation, a Delaware corporation (“Purchaser”) and a wholly owned subsidiary of Bruker Corporation, a Delaware corporation (“Bruker”), is offering to purchase all of the outstanding shares of common stock, par value $0.00005 per share (the “Shares”), of PhenomeX Inc., a Delaware corporation (“PhenomeX”), for $1.00 per Share, net to …May 11, 2023 · PhenomeX Inc. (CELL) delivered earnings and revenue surprises of -11.11% and 3.52%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? PhenomeX's Beacon platform is protected by a growing portfolio of PhenomeX Inc. (Nasdaq: CELL), the functional cell biology company, today announced that the series of lawsuits filed by AbCellera ...UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Ex...Nov 23, 2023 · Preliminary SpotLight™ Human Lambda reagent data to be showcased by GSK at the 16 th annual PEACe Conference. EMERYVILLE, Calif., Sept. 21, 2023 /PRNewswire/ -- PhenomeX Inc. (Nasdaq: CELL), a ...

Following the close of the transaction, Berkeley Lights shareholders will own approximately 75.2 percent of the combined company, and IsoPlexis shareholders will own approximately 24.8 percent of the combined company. “The combination of Berkeley Lights and IsoPlexis represents an important milestone and fuels our transformation into a ...On March 21, 2023, PhenomeX assumed 304,619 IsoPlexis RSAs and 378,767 IsoPlexis stock options after applying the 0.612 conversion ratio. The Company accounted for the assumed equity awards as a modification under ASC 718 and recorded stock compensation expense of $0.1 million during the three months ended March 31, 2023 associated with …

Bruker Corporation signed a definitive agreement to acquire PhenomeX Inc. for approximately $110 million on August 17, 2023. Pursuant to the Merger Agreement, Bruker Corporation will acquire all of...The removal of selected endocrine disrupter compounds (EDCs), namely estrone (E1), 17β-estradiol (E2), 17α-ethynylestradiol (EE2), bisphenol A (BPA) and 4-tert-octylphenol (4t-OP) from municipal wastewater was investigated using a sequencing batch biofilter granular reactor (SBBGR), a new technology for biological treatment based on …• Calibration and Quality Control Samples: Stock solution of (S)-Amlodipine and (R)-Amlodipine were prepared in methanol at the concentration of 1mg/mL. Working standard solutions of various concentrations for spiking into plasma were prepared with methanol: water (50:50v/v). Working stock of internal standard was prepared at the concentration ofBerkeley Lights (Nasdaq: BLI) and IsoPlexis (Nasdaq: ISO) today announced a definitive agreement under which Berkeley Lights will acquire IsoPlexis in an all-stock transaction valued at $57.8 million.43.0%. -36.3%. Market Cap. The market value of a company, in total dollars, also called "market capitalization." Market cap is calculated by taking a company's price per share and multiplying it ...Acquisition initiates Bruker’s entry into functional single-cell biology research solutions. BILLERICA, Mass. & EMERYVILLE, Calif.--(BUSINESS WIRE)--#BRKR--Bruker Corporation (Nasdaq: BRKR) and PhenomeX Inc. (Nasdaq: CELL) today announced that they have signed a definitive agreement for Bruker to acquire PhenomeX for $1.00 per …

Aug 31, 2023 · 3. The Offer is being made pursuant to an Agreement and Plan of Merger, dated August 17, 2023 (as it may be amended from time to time, the “Merger Agreement”), by and among PhenomeX, Bruker and Purchaser, pursuant to which, after consummation of the Offer and the satisfaction or waiver of certain conditions, Purchaser will merge with and into PhenomeX pursuant to Section 251(h) of the ...

Company profile page for PhenomeX Inc including stock price, company news, press releases, executives, board members, and contact information

All. News. Press Releases. Find the latest PhenomeX Inc. (CELL) stock quote, history, news and other vital information to help you with your stock trading and investing. At the Effective Time, each outstanding option to purchase common stock, par value $0.001, of IsoPlexis (“IsoPlexis Common Stock”) (whether vested or unvested) held by continuing IsoPlexis employees with a per share exercise price less than the average closing trading price for a share of IsoPlexis Common Stock rounded to the nearest one …The stock market is getting a jolt from the inflation report. All three major U.S. stock indexes jumped more than 1% Tuesday morning, with the coming close to a 2% gain.Nov 23, 2023 · Preliminary SpotLight™ Human Lambda reagent data to be showcased by GSK at the 16 th annual PEACe Conference. EMERYVILLE, Calif., Sept. 21, 2023 /PRNewswire/ -- PhenomeX Inc. (Nasdaq: CELL), a ... WHEREAS, on the terms and subject to the conditions set forth in this Agreement, Merger Sub has agreed to commence (within the meaning of Rule 14d-2 under the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (the “Exchange Act”)), a cash tender offer to acquire any and all of the outstanding shares of the Company Common Stock for $1.00 per ...Aug 17, 2023 · PhenomeX Inc. CELL stock has more than doubled on Thursday after Bruker Corp. BRKR, +1.49% said it would acquire the Emeryville, Calif.-based, cell biology company for $1 a share in a deal that... PhenomeX (Nasdaq: CELL), the functional cell biology company, today announced that Yan Zhang, Ph.D., has been named chief commercial officer (CCO), effective immediately. In addition to Dr. Zhang ...The DI4G 10 mM stock solution was prepared in DMSO. The assay solutions were obtained by addition of 50 μL of a solution containing the substrates (10 mM phosphate buffer, pH 7.0 and 765 μM Ino) and different volumes of the DI4G solutions (0.05, 10, and 500 μM) in H 2 O/DMSO (9:1, v/v).Return On Tangible Equity. Current and historical return on assets (ROA) values for PhenomeX (CELL) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. ROA - Return on Assets Historical Data.

Webull offers Phenomex stock information, including NASDAQ: CELL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, …WebOct 3, 2023 · During its Q3 2023 earnings release, Bruker will provide more details on the expected Q4 2023 effect from PhenomeX. Today, Bruker reconfirms its medium-term financial outlook as issued at its Investor Day in June 2023. As a result of the transaction closing, PhenomeX common stock will no longer be listed for trading on the Nasdaq Global Market. Jan 3, 2023 · Berkeley Lights (Nasdaq: BLI) and IsoPlexis (Nasdaq: ISO) today announced a definitive agreement under which Berkeley Lights will acquire IsoPlexis in an all-stock transaction valued at $57.8 million. PhenomeX to begin trading under symbol (NASDAQ: CELL) EMERYVILLE, Calif., March 21, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (Nasdaq: BLI), a life sciences tools company, today announced that it has completed its previously announced acquisition of Isoplexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the …Instagram:https://instagram. bnd dividendverb tech newsjcpuxvroom stock EMERYVILLE, Calif., May 09, 2022 -- Berkeley Lights, Inc. , a leader in digital cell biology, today reported financial results for the quarter ended March 31, 2022. Recent Highlights ...PhenomeX (Nasdaq: CELL), the functional cell biology company, today announced that Peter Silvester has been named to the PhenomeX board of directors, effective immediately. ... The stock market is ... australia stock brokersmovinginsurance.com reviews PhenomeX Inc. (CELL) delivered earnings and revenue surprises of -11.11% and 3.52%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? how to learn cryptocurrency trading Bruker considers PhenomeX as a pivotal investment in its strategy, Project Accelerate 2.0, which is focused on their Spatial Biology and Cellular Analysis segment. Bruker considers the PhenomeX optofluidics and proteomics technologies a key addition to their technology to build out their offerings in single cell biology, proteomics cellular analysis, multi-omics, …66.06. +0.97. +1.49%. PhenomeX Inc. (Nasdaq: CELL) today announced that Bruker Corporation (Nasdaq: BRKR) has commenced, through its wholly owned …Web